C
Carolyn A. Felix
Researcher at Children's Hospital of Philadelphia
Publications - 110
Citations - 5898
Carolyn A. Felix is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Leukemia & Chromosomal translocation. The author has an hindex of 44, co-authored 108 publications receiving 5676 citations. Previous affiliations of Carolyn A. Felix include Roswell Park Cancer Institute & Women & Children's Hospital of Buffalo.
Papers
More filters
Journal ArticleDOI
Secondary leukemias induced by topoisomerase-targeted drugs
TL;DR: With few exceptions, treatment-related leukemias respond less well to either chemotherapy or bone marrow transplantation than their de novo counterparts, necessitating more innovative treatments, a better mechanistic understanding of the pathogenesis, and strategies for prevention.
Journal ArticleDOI
High incidence of secondary brain tumours after radiotherapy and antimetabolites
Mary V. Relling,Mary V. Relling,Jeffrey E. Rubnitz,Jeffrey E. Rubnitz,Gaston K. Rivera,Gaston K. Rivera,James M. Boyett,James M. Boyett,Michael L. Hancock,Michael L. Hancock,Carolyn A. Felix,Larry E. Kun,Larry E. Kun,Andrew W. Walter,Andrew W. Walter,William E. Evans,William E. Evans,Ching-Hon Pui,Ching-Hon Pui +18 more
TL;DR: Data support the elimination of prophylactic radiotherapy for acute lymphoblastic leukaemia except in patients at high risk of central-nervous-system relapse and underlying genetic characteristics and treatment variables may be associated with an increased risk of radiation-associated brain tumours.
Journal ArticleDOI
Association of CYP3A4 genotype with treatment-related leukemia
Carolyn A. Felix,Amy H. Walker,Beverly J. Lange,Terence M. Williams,Naomi J. Winick,Nai-Kong V. Cheung,Brian D. Lovett,Peter C. Nowell,Ian A. Blair,Timothy R. Rebbeck +9 more
TL;DR: The data suggest that individuals with CYP3A4-W genotype may be at increased risk for treatment-related leukemia and that epipodophyllotoxin metabolism by CYP 3A4 may contribute to the secondary cancer risk.
Journal ArticleDOI
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
Anita R. Mistry,Carolyn A. Felix,Ryan J. Whitmarsh,Annabel Mason,Andreas Reiter,Bruno Cassinat,A Parry,Christoph Walz,Joseph L. Wiemels,Mark R. Segal,Lionel Ades,Ian A. Blair,Neil Osheroff,Andrew Peniket,Marina Lafage-Pochitaloff,Nicholas C.P. Cross,Christine Chomienne,Ellen Solomon,Pierre Fenaux,David Grimwade +19 more
TL;DR: Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomersase II poisons.
Journal ArticleDOI
Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group
Logan G. Spector,Yang Xie,Leslie L. Robison,Nyla A. Heerema,Joanne M. Hilden,Beverly J. Lange,Carolyn A. Felix,Stella M. Davies,Joanne L. Slavin,John D. Potter,Cindy K. Blair,Gregory H. Reaman,Julie A. Ross +12 more
TL;DR: Overall, maternal consumption of fresh vegetables and fruits during pregnancy was associated with a decreased risk of infant leukemia, particularly MLL+.